|
Oct 9
|
Offering Wegovy and other weight loss drugs on Medicare could cost $35 billion
|
|
Oct 9
|
Got $5,000? These 3 Growth Stocks Are on Sale Right Now.
|
|
Oct 9
|
Implied Volatility Surging for Novo Nordisk (NVO) Stock Options
|
|
Oct 9
|
Novo Nordisk A/S (NVO) Bullish on Wegovy Launch in International Markets
|
|
Oct 9
|
Ozempic and prescription weight loss drugs: How they work, what they cost, side effects, and everything to know
|
|
Oct 8
|
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
|
|
Oct 8
|
WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering
|
|
Oct 8
|
WeightWatchers Is Offering Knockoff Wegovy. The Market Is Already Crowded.
|
|
Oct 8
|
Novo Nordisk Advances Share Buyback Program
|
|
Oct 8
|
Prediction: 3 of Wall Street's Most Influential Stocks Can Plunge if Kamala Harris Wins in November
|
|
Oct 3
|
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
|
|
Oct 3
|
A mayor promises Ozempic for all and says there 'will be no more fat people' in his city
|
|
Oct 3
|
Chronic diseases “as urgent as climate change,” says Novo Nordisk CSO
|
|
Oct 3
|
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers.
|
|
Oct 3
|
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
|
|
Oct 2
|
European Equities Close Mostly Higher in Wednesday Trading; Euro Area Unemployment Unchanged in August
|
|
Oct 2
|
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
|
|
Oct 2
|
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
|
|
Oct 1
|
Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
|
|
Oct 1
|
Novo Nordisk has mitigation plans to minimize disruption from port strikes
|